is glp-1 covered by blue cross blue shield to stop covering popular weight-loss drugs does blue cross blue shield

SUSTAIN-6 evaluated once-weekly semaglutide versus placebo in patients at moderate and high cardiovascular risk with type 2 diabetes, showing a 26% relative risk reduction in MACE (HR 0.74, 95% CI 0.58 to 0.95)

Both Neeland and Ahmed say more research is needed on the health effects from short-term use of GLP-1s

Supplier evaluation criteria that actually matter Not all suppliers are created equal, and the cheapest option is rarely the best value

GLP-1 safety: While FDA-approved for weight management, these medications can cause gastrointestinal side effects and should be monitored by a healthcare provider

That is a softer claim than it is Ozempic in a patch, but it still suggests major physiological impact

The same module found a 20% increase in metoprolol Cmax (unchanged AUC), also deemed not clinically significant [1]